The safety of vaccines is fundamental to maintaining social stability.
We persist in developing a full-process quality management system covering R&D, manufacturing and release, and have set clear management requirements for employees and facilities involved in each link, including specific management objects such as suppliers, laboratories, facilities, manufacturing workshops, etc.. We aim to ensure vaccine quality from the source, reducing potential safety risks, and provide reliable immune protection for the public.
Vaccine production facilities compliant with international quality standards .
Our quality management certified for GMP by China, the European Union, and WHO.
We have constructed large-scale modernized vaccine manufacturing bases in Tianjin and Shanghai in China, with over 200,000 square meters.
In Tianjin, we have a campus of nearly 130,000 square meters. Built with a total investment of nearly RMB 10 billion, it is able to produce 280 million doses of vaccines a year on the existing production lines.
In Shanghai, we are building a facility for our mRNA vaccine at the Life Blue Bay Industrial Park of the Lin-gang Special Area. This facility will probe into the key technologies for the production of mRNA vaccines. The investment in Phase 1 is over RMB 1 billion, and the plan is to build a facility of about 17,000 square meters.
CanSinoBIO Shanghai is at the core of the company’s strategy for upgrading to the next level
It is the company's R&D center, production center, business center, and shareholding center. Revolving around the mRNA platform, this facility conducts early studies for preventive vaccines and innovative therapeutics, develops production processes for them, carries out their pilot production and scale-up, engages in the commercial production of drugs, and seeks international cooperation.
We leverage vaccine technology to reach across the globe and assist numerous nations in setting up localized production facilities, showcasing our exceptional capacity to combat the pandemic.
Local fill-and-finish production lines have been set up in Mexico, Pakistan, and Malaysia to establish joint manufacturing. We also helped Pakistan, Mexico, Malaysia and other developing countries build filling lines through technology transfer, to achieve the local production of our COVID-19 vaccine, to expand the joint production of our COVID-19 vaccine overseas, and to demonstrate our strength in combating COVID-19 to the world.
